A Phase I, Multicenter Dose-Escalation Study to Assess the Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AZD5153 in Patients With Relapsed/Refractory Malignant Solid Tumors, Including Lymphomas
Phase of Trial: Phase I
Latest Information Update: 20 Aug 2017
At a glance
- Drugs AZD 5153 (Primary)
- Indications Lymphoma; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 17 Jul 2017 Planned End Date changed from 9 Jan 2019 to 3 Jan 2019.
- 17 Jul 2017 Planned primary completion date changed from 9 Jan 2019 to 3 Jan 2019.
- 17 Jul 2017 Status changed from not yet recruiting to recruiting.